Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT2 | P31751 | 6/20 | 1.00 |
| ▸ | GSK3B | P49841 | 3/20 | 1.00 |
| ▸ | KIT | P10721 | 1/20 | 1.00 |
| ▸ | LCK | P06239 | 1/20 | 0.76 |
| ▸ | JAK3 | P52333 | 9/20 | 0.72 |
| ▸ | DOT1L | Q8TEK3 | 2/20 | 0.71 |
| ▸ | HTR2C | P28335 | 1/20 | 0.68 |
| ▸ | JAK2 | O60674 | 1/20 | 0.58 |
| ▸ | JAK1 | P23458 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30673936 | 1.00 | AKT2 (1.00) | AKT2GSK3BKITLCKJAK3 | |
| Hydrochloric Acid SCHEMBL29036033 | 0.98 | AKT2 (0.97) | AKT2GSK3BKITLCKJAK3 | |
| SCHEMBL15178732 | 0.91 | DOT1L (0.85) | AKT2GSK3BKITLCKJAK3 | |
| SCHEMBL10074309 | 0.91 | DOT1L (0.85) | AKT2GSK3BKITLCKJAK3 | |
| SCHEMBL2019251 | 0.91 | AKT2 (0.83) | AKT2GSK3BKITLCKJAK3 | |
| SCHEMBL15456272 | 0.90 | AKT2 (0.82) | AKT2GSK3BKITLCKJAK3 | |
| Hydrochloric Acid SCHEMBL15170166 | 0.90 | DOT1L (0.82) | AKT2GSK3BKITLCKJAK3 | |
| Hydrochloric Acid SCHEMBL15169727 | 0.90 | DOT1L (0.82) | AKT2GSK3BKITLCKJAK3 | |
| SCHEMBL2022699 | 0.88 | AKT2 (0.78) | AKT2GSK3BKITLCKJAK3 | |
| SCHEMBL2019457 | 0.87 | LCK (1.00) | AKT2GSK3BKITLCKJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3719018-B1 | PURINE AND DEAZAPURINE DERIVATIVES AS PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LTD (GB) | 2025-08-27 | — | — | EP | claimed |
| WO-2023238919-A1 | HYBRID TYPE COMPOUND OR SALT THEREOF | 渡部 良広 | 2023-12-14 | — | — | WO | claimed |
| EP-3719018-B1 | PURINE AND DEAZAPURINE DERIVATIVES AS PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LTD (GB) | 2025-08-27 | — | — | EP | disclosed |
| WO-2024175998-A1 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | DUNAD THERAPEUTICS, LTD. (GB) | 2024-08-29 | — | — | WO | disclosed |
| CN-118146226-A | Pyrrolo [2,3-d ] pyrimidine compound with nitrogen-containing heterocyclic structure, and preparation method and application thereof | 贵州大学 | 2024-06-07 | — | — | CN | disclosed |
| WO-2023238919-A1 | HYBRID TYPE COMPOUND OR SALT THEREOF | 渡部 良広 | 2023-12-14 | — | — | WO | disclosed |
| WO-2023238919-A1 | HYBRID TYPE COMPOUND OR SALT THEREOF | 渡部 良広 | 2023-12-14 | — | — | WO | disclosed |
| US-20220411420-A1 | PYRROLOPYRIMIDINE DERIVATIVE HAVING ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE INHIBITORY ACTIVITY AND USE THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2022-12-29 | — | — | US | disclosed |
| EP-2892534-B1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2021-08-04 | — | — | EP | disclosed |
| EP-3421471-B1 | PURINE AND DEAZAPURINE DERIVATIVES AS PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LTD (GB) | 2021-05-26 | — | — | EP | disclosed |
| EP-3421471-B1 | PURINE AND DEAZAPURINE DERIVATIVES AS PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LTD (GB) | 2021-05-26 | — | — | EP | disclosed |
| US-20090247538-A1 | Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors | ASTEX THERAPEUTICS LIMITED (UK) | 2009-10-01 | — | — | US | disclosed |
| CN-101489559-A | Purine and deazapurine derivatives as pharmaceutical compounds | ASTEX THERAPEUTICS LTD (GB) | 2009-07-22 | — | — | CN | disclosed |
| CN-101484173-A | Pharmaceutical combinations of pk inhibitors and other active agents | ASTEX THERAPEUTICS LTD (GB) | 2009-07-15 | — | — | CN | disclosed |
| EP-2043655-A2 | PURINE AND DEAZAPURINE DERIVATIVES AS PHARMACEUTICAL COMPOUNDS | Astex Therapeutics Limited (GB) | 2009-04-08 | — | — | EP | disclosed |
| US-20090082370-A1 | Pharmaceutical Combinations of PK Inhibitors and Other Active Agents | ASTEX THERAPEUTICS LIMITED (GB) | 2009-03-26 | — | — | US | disclosed |
| EP-2037931-A2 | PHARMACEUTICAL COMBINATIONS OF PK INHIBITORS AND OTHER ACTIVE AGENTS | Astex Therapeutics Limited (GB) | 2009-03-25 | — | — | EP | disclosed |
| WO-2007125321-A2 | PURINE AND DEAZAPURINE DERIVATIVES AS PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007125321-A2 | PURINE AND DEAZAPURINE DERIVATIVES AS PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007125310-A2 | PHARMACEUTICAL COMBINATIONS OF PK INHIBITORS AND OTHER ACTIVE AGENTS | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411420-A1 | PYRROLOPYRIMIDINE DERIVATIVE HAVING ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE INHIBITORY ACTIVITY AND USE THEREOF | ENPP1, ENPP3, PPA1 | AKT2 1623/4885GSK3B 942/4885KIT 4808/4885 |
| US-20090247538-A1 | Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors | CDK2, CDK1, OXSR1 | AKT2 496/4885GSK3B 644/4885KIT 2780/4885 |
| US-20090082370-A1 | Pharmaceutical Combinations of PK Inhibitors and Other Active Agents | PKN2, PKN1, PKN3 | AKT2 523/4885GSK3B 109/4885KIT 2305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.